Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children

被引:28
作者
Marsit, Hanen [1 ,2 ]
Philippe, Michael [3 ]
Neely, Michael [4 ,5 ]
Rushing, Teresa [5 ,6 ]
Bertrand, Yves [3 ]
Ducher, Michel [7 ,8 ]
Leclerc, Vincent [7 ,8 ]
Guitton, Jerome [8 ,9 ]
Bleyzac, Nathalie [7 ,8 ]
Goutelle, Sylvain [1 ,7 ,10 ]
机构
[1] Univ Lyon 1, Lab Biometrie & Biol Evolut, Univ Lyon, UMR 5558,CNRS, Villeurbanne, France
[2] Univ Monastir, Fac Pharm, Monastir, Tunisia
[3] Inst Hematol & Oncol Pediat, Lyon, France
[4] Childrens Hosp Los Angeles, Div Pediat Infect Dis, Lab Appl Pharmacokinet & Bioinformat, Los Angeles, CA 90027 USA
[5] Univ Southern Calif, Los Angeles, CA 90007 USA
[6] Childrens Hosp Los Angeles, Pharm Dept, Los Angeles, CA 90027 USA
[7] Hosp Civils Lyon, Grp Hosp Nord, Serv Pharm, Hop Pierre Garraud, 136 Rue Commandant Charcot, F-69005 Lyon, France
[8] Univ Lyon 1, Univ Lyon, EMR 3738 PK PD Modeling Oncol & Hematol, Lyon, France
[9] Hosp Civils Lyon, Grp Hosp Sud, Lab Pharmacol & Toxicol, Lyon, France
[10] Univ Lyon 1, Univ Lyon, ISPB, Fac Pharm Lyon, Lyon, France
关键词
POPULATION PHARMACOKINETICS; PEDIATRIC-PATIENTS; MARROW TRANSPLANT; EXPOSURE; THERAPY; COHORT; BLOOD; MODEL; METRONIDAZOLE; METABOLISM;
D O I
10.1007/s40262-020-00877-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Busulfan therapeutic drug monitoring (TDM) is necessary to better achieve the target exposure in children before hematopoietic stem cell transplantation (HSCT). However, TDM-based dosing may be challenging if intra-individual pharmacokinetic variability (also denoted inter-occasion variability [IOV]) occurs during therapy. Objectives The objectives of this study were to describe and quantify busulfan IOV in children, and to investigate its potential determinants. Methods We performed a new analysis of published data from children who received intravenous busulfan over 4 days before HSCT. We calculated individual pharmacokinetic parameters on each day of therapy using a published population pharmacokinetic model of busulfan and analyzed their changes. Population estimation of IOV was also performed with non-linear mixed effects (NLME) modeling. Potential predictors of significant decrease in busulfan clearance (CL) were assessed by using machine learning approaches. Results IOV could be assessed in 136 children. Between day (D) 1 and D2, most patients (80%) experienced a decrease in busulfan CL, with a median change of - 7.9%. However, both large decreases (minimum, - 48.5%) and increases in CL (maximum, + 44%) were observed. Over D1-D3 of therapy, mean CL significantly decreased (- 15%), with a decrease of >= 20% in 22% of patients. Some patients also showed unstable CL from day to day. NLME modeling of IOV provided a coefficient of variation of 10.6% and 13.1% for volume of distribution (V-d) and CL, respectively. Some determinants of significant decreases in busulfan CL were identified, but predictive performance of the models was limited. Conclusions Significant busulfan intra-individual variability may occur in children who receive a HSCT and is hardly predictable. The main risk is busulfan overexposure. Performing TDM repeatedly over therapy appears to be the best way to accurately estimate busulfan exposure and perform precision dosing.
引用
收藏
页码:1049 / 1061
页数:13
相关论文
共 38 条
[11]  
Eva C, 2018, THER DRUG MONIT, V40, P84, DOI 10.1097/FTD.0000000000000468
[12]  
Gulbis Alison M, 2011, Ann Pharmacother, V45, pe39, DOI 10.1345/aph.1Q087
[13]   Cancer, Inflammation, and Therapy: Effects on Cytochrome P450-Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents [J].
Harvey, R. Donald ;
Morgan, E. T. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (04) :449-457
[14]   INFLUENCE OF PROPHYLACTIC ANTICONVULSANT THERAPY ON HIGH-DOSE BUSULFAN KINETICS [J].
HASSAN, M ;
OBERG, G ;
BJORKHOLM, M ;
WALLIN, I ;
LINDGREN, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (03) :181-186
[15]  
KIM B, 2017, SCI REP, V7, DOI DOI 10.1038/S41598-017-01861-75431879
[16]   Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination of Optimal Once-Daily Busulfan Dose Using Pharmacokinetic Modeling [J].
Lee, Ji Won ;
Kang, Hyoung Jin ;
Lee, Seung Hwan ;
Yu, Kyung-Sang ;
Kim, Nam Hee ;
Yuk, Yen Ju ;
Jang, Mi Kyoung ;
Han, Eun Jong ;
Kim, Hyery ;
Song, Sang Hoon ;
Park, Kyung Duk ;
Shin, Hee Young ;
Jang, In-Jin ;
Ahn, Hyo Seop .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (06) :944-950
[17]  
Lindley C, 2004, ANTI-CANCER DRUG, V15, P453, DOI 10.1097/01.cad.0000127145.50172.51
[18]   Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant: A Model-Based Dosing Algorithm for Personalized Therapy and Implementation Into Routine Clinical Use [J].
Long-Boyle, Janel R. ;
Savic, Rada ;
Yan, Shirley ;
Bartelink, Imke ;
Musick, Lisa ;
French, Deborah ;
Law, Jason ;
Horn, Biljana ;
Cowan, Morton J. ;
Dvorak, Christopher C. .
THERAPEUTIC DRUG MONITORING, 2015, 37 (02) :236-245
[19]   Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality [J].
McCune, Jeannine S. ;
Batchelder, Ami ;
Deeg, H. Joachim ;
Gooley, Ted ;
Cole, Scott ;
Phillips, Brian ;
Schoch, H. Gary ;
McDonald, George B. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (07) :853-862
[20]   Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization [J].
McCune, Jeannine S. ;
Bemer, Meagan J. ;
Barrett, Jeffrey S. ;
Baker, K. Scott ;
Gamis, Alan S. ;
Holford, Nicholas H. G. .
CLINICAL CANCER RESEARCH, 2014, 20 (03) :754-763